Submit your Axumin® (Fluciclovine F 18) injection patient case studies

Axumin real-world case studies are a valuable way to illustrate how Axumin can detect and localize recurrent prostate cancer. 

If you would like to submit an Axumin case study, please complete the form below. A member of the Blue Earth Diagnostics Medical Affairs team will be in contact with you to follow up regarding case study details.

Address Container
Address
I agree that a representative from Blue Earth Diagnostics can contact me about submitting a case study. I also agree that I will remove all identifying patient information from the case details that I submit to Blue Earth Diagnostics, including removing patient name from all scan images prior to submission.

INDICATION

Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

  • Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
  • Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
  • Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
  • Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Axumin full Prescribing Information.